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Abstract
Nonalcoholic fatty liver disease (NAFLD) is increasingly
recognized as an important public health problem
nowadays. NAFLD encompass a variety of liver
pathologies including simple steatosis, NASH, fibrosis,
cirrhosis and finally cancer. It is associated with obesity,
metabolic syndrome, dyslipidaemia, Insulin resistance (IR)
and type 2 diabetes.
It is the most common chronic liver disease in USA and
considered to be increasing in Asia Pacific region
including South Asia however there is no community
based study from Pakistan. Customarily NAFLD had been
regarded as a benign disease; however clinical as well as
epidemiological studies had contradicted this belief
because approximately 20% of the patients with NAFLD
had NASH which has propensity to develop cirrhosis and
ultimately to HCC.
The diagnosis of NAFLD is made most of the times
incidentally on abdominal imaging which is done for
other purposes.
Despite its prevalence, treatment options are very limited.
However modification of risk factors such as dyslipidemia,
diabetes control and weight reduction does help in
NAFLD. Fatty liver results due to lack of physical activity;
hence foremost step to manage such patients would be
to develop the healthy life style. We need population
based studies in our country so that we can protect our
population from a new epidemic.   
Keywords: NAFLD, NASH, Fatty liver, Physical activity,
Hepatocellular carcinoma.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is recognized as
an important public health problem nowadays. NAFLD
encompass a variety of liver pathologies including simple
steatosis, Nonalcoholicsteatohepatitis (NASH), fibrosis,
cirrhosis and finally cancer.1-4
Approximately three decades ago Ludwig et al described
liver lesions similar to alcohol associated lesions within
liver in patients who did not take alcohol and called it
NAFLD.5 NAFLD is defined as fatty liver (Liver fat > 5-10%
of liver weight) which is not due to excess alcohol or other
cause of steatosis. NAFLD is associated with obesity,
metabolic syndrome, dyslipidemia, insulin resistance (IR)
and type 2 diabetes.6 However, exact pathogenesis of
NAFLD is incompletely understood and factors that
determine the severity are still to be clearly understood.2
NAFLD is the most common chronic liver disease in USA
and considered to be increasing in Asia pacific region
including South Asia.2,7 NAFLD affects approximately 15-
40% of general population and its prevalence is
increasing worldwide.1,2,8 The community prevalence of
NAFLD in South Asia and South East Asia ranges from 5-
30%. Recently a hospital based study in Pakistan had
shown a frequency of approximately 14% however, there
is no community based study from Pakistan to the best of
our knowledge.9 In India it varies from 5-28% in general
population especially those who are undergoing healthy
checkups. Indians have increased propensity for visceral
fat accumulation which may present from birth.7,10,11 In
China, prevalence ranges from 5-24% higher in urban
areas, compared to rural areas. Fatty liver on ultrasound
was detected in 18% of white collar people in Beijing and
11% in labourers and similar figures were reported from
other areas of Shanghai.7,12 Other countries like Japan,
Hong Kong, Taiwan, Indonesia have a prevalence of 9-
14%,16%,11-41% and 30% respectively.7
Customarily NAFLD had been regarded as a benign
disease; however clinical as well as epidemiological
studies have contradicted this belief and have shown that
approximately 20% of the patients with NAFLD had
Nonalcoholic steatohepatitis (NASH). This NASH group
constituted approximately 80% of cryptogenic cirrhosis
and progressed to advanced fibrosis in 32-37%.13 Certain
risk factors are associated with NAFLD like obesity, type II
diabetes mellitus (Type 2 DM) and insulin resistance.
These risk factors increase the risk of fibrosis progression.
Hence, about 5-20% of patients with Non cirrhotic NASH
would develop cirrhosis in 10 years and about one in
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every 200 NASH subject would develop hepatocellular
carcinoma (HCC) over a 7 years period.14-16 Second most
common cause of death in patients with NASH is liver
disease (cirrhosis related complications) causing 12%
deaths in 10 years of follow up.1 Hence, it is clear that
NASH cannot be considered as benign disease anymore.
The available literature shows that clinical and social
burden of NAFLD continues to increase.
Pathogenesis:
The pathogenesis of NAFLD is still incompletely
understood and factors which determine disease are still
not very clear nevertheless, overweight/obesity and
insulin resistance are considered as risk factors.2 Typically,
patients at the time of diagnosis are of middle age. The
prevalence of other diseases being risk factors for NAFLD,
are also increasing. For example majority of patients
(>80%) are overweight with approximately 30% being
obese, 30-70% are hypertensive and 20% have Type 2
DM.1,17 Therefore NAFLD has been considered as part of
metabolic syndrome.1
NAFLD may present with a variety of signs and symptoms
including insulin resistance (IR), peripheral lipolysis,
increased hepatic uptake of fatty acids, hormonal
abnormalities (elevated leptin), release of pro-inflammatory
cytokines and elevated insulin level induced mitochondrial
function abnormality. All these abnormalities start the
cascade of NAFLD from simple fatty liver to NASH and result
in decompensated cirrhosis or HCC.1
Diagnosis:
The diagnosis of NAFLD is made on abdominal imaging
for evaluation of elevated liver enzymes or for some other
indications. Most of the patients are asymptomatic. If
symptoms develop, these are nonspecific such as fatigue
or upper abdomen pain.3 Majority patients seek medical
consultation because of deranged liver functions seen as
elevated liver enzymes. The population based data such
as 3rd National Health and Nutrition Examination Survey
(NHAHES III) from North America has shown prevalence of
deranged liver enzymes in 8% and in 2/3 cases centre
could not be determined. Most of these unexplained
abnormal liver functions are strongly associated with
metabolic syndrome and hence represent possible
NAFLD.18 However, transaminase levels are typically
normal or elevated by <5 times of upper limit of normal.19
In contrast to those with alcoholic hepatitis, most patients
with NAFLD had ratio of aspartate aminotransferase (AST)
to alanine aminotransferase (ALT) of less than 1. As the
disease progresses, AST level increases more than ALT
level, and if the ratio is greater than 1, more advanced liver
disease may be suspected.20
Recent studies suggest that upper limit of normal for
serum ALT (generally between 40 and 55 IU/L) should be
lowered to <30 IU/L for men and <19 IU/L for women.21
The assessment of patients with NAFLD includes
confirmation of diagnosis, disease severity assessment to
differentiate between NAFLD/NASH and to determine the
concomitant metabolic abnormalities including insulin
resistance and cardiovascular abnormalities.
The current guidelines recommend hepatic
ultrasound(US) as first step of diagnostic evaluation of
NAFLD. The ultrasound features of NAFLD include
increased hepatic echogenicity, vascular blurring and
deep attenuation of US signals. These three US features
had good accuracy in detecting fatty liver and had good
correlation with visceral obesity and metabolic syndrome
(MetS).22,23 NAFLD diagnosis also requires exclusion of
other liver conditions such as viral hepatitis (HBV, HCV) and
alcoholic liver disease.3 Liver histology remains the gold
standard for assessing disease severity in NAFLD. Being
invasive, biopsy is unsuitable for community studies and
particularly for studying hepatic fibrosis progression, and
also histological assessment of NAFLD is associated with
sampling error and can lead to underestimation of the
fibrosis score especially when specimen is small.3
It is now however, clear that NAFLD and insulin resistance
(IR) have a 'chicken and egg' type relationship where each
supports the other.18 Insulin resistance has been directly
linked to development of diabetes mellitus, hypertension,
and atherosclerosis and all these lead to significant
morbidity and mortality.19
Recently Asia pacific society of liver diseases has
incorporated the anthropometric measurements as
regional criteria based on multiple Asian publications.
Majority of patients with NAFLD are overweight or obese,
therefore small increases in weight such as 2-3kg in body
weight may lead to NAFLD, but more importantly this may
occur within the normal ranges of weight.24 The World
Health Organization (WHO) has redefined the criteria of
obesity for Asians when body mass index (BMI) is>25
Kg/m2 and overweight when BMI is between 23-25Kg/m2.3
Unlike hospital based studies, population based studies
have defined NAFLD by biochemical criteria (increased
serum transamainases or gamma glutamyltranspeptidase)
or by hepatic imaging (liver US, Computerized tomography
i-e CT, magnetic resonance imaging) or both. Therefore, an
operational definition of NAFLD based on liver imaging,
supported by appropriate exclusion, appears sustainable
and can overcome some of the problems associated with
liver biopsy.3 Hence, deciding for operational definition of
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NAFLD in South Asia, cost and availability should be
considered before defining for clinical as well as research
purpose. Literature shows that CT may not carry more
weightage than US in terms of diagnosis and CT may only
be useful in identifying focal fatty change in liver. Magnetic
resonance imaging (MRI) can be robust for NAFLD because
it can quantify the triglycerides stores in liver that can be
useful in assessing the efficacy of therapeutic intervention,
but this modality is very expensive and not available
everywhere in this part of world (South Asia).3 In Japan US
liver has been used for NAFLD as a standard of care.25 In one
of the comparative study from Cleveland clinic, which used
liver histology ( at least 30% fat) as the gold standard,
sensitivity and specificity of liver US for NAFLD was good
(89% and 93% respectively), but somewhat less for liver
fibrosis (77% and 89% respectively).26
Treatment:
Despite its prevalence, treatment options are very limited.
However, modification of risk factors such as dyslipidaemia,
control of diabetes and weight reduction helps in control of
NAFLD.27 Fatty liver occurs due to lack of physical activity,
excess calorie intake in comparison to normal person
without fatty liver, hence, the foremost step to advise such
patients to develop a healthy life style.4 When such
intervention proves to be ineffective then one should go
for drugs which would be the second line strategy. Often, it
is difficult to encourage people to modify their unhealthy
behaviour to adopt healthier life style because life style
modifications depend largely on personal beliefs and
values. Therefore psychological/ behavior strategies are
essential to produce a change in behaviour.
Lifestyle modification:
Behavioral therapy: 
Behavioral therapy is an area of research widely applied to
the treatment of obesity and associated metabolic
diseases. This type of therapy is a global therapeutic
approach which delivers patients the practical approach to
achieve their eating and exercise goals. Subjects are
administered with a set of principles and techniques for
modifying diet and exercise such as keeping records of
their daily food intake along with physical activity, counting
food calories and the time spent in exercise, being more
active in their daily life, avoiding situations which could
lead to incidental eating and correcting unrealistic goals
about weight loss and body image.4 This type of therapy is
usually offered in groups of 10-15 subjects or occasionally
individually but preferable in groups; in weekly sessions of
60-90 minutes for a period of 3-12 months.4,28 Patients learn
to calculate food calories, manage their nutritional changes
and are encouraged to do physical exercise for 30-40 min
daily for at least 5 days a week.4,29 This type of intensive
programme often leads to a mean weight loss of 10% of
initial weight in 6 months in subjects who complete the
treatment. Unfortunately some patients regain part of their
lost weight within one year but majority maintain healthy
weight loss of < 5% bodyweight by following treatment
and weight maintenance strategies.30-31 Recently a meta-
analysis also confirmed that lifestyle intervention is at least
as effective as pharmacotherapy.32 This was also seen in a
study done in India which revealed that moderate physical
activity and diet was effective in preventing diabetes in
Indians despite having low BMI.28 Behavioral therapy
requires a well-defined programme, must be supported by
a manual for both operators and patients, and must be
carried out by a multidisciplinary team, including
physicians, dieticians, psychologists, trained nurses and
physical exercise experts.30-33 There are several techniques
that aim at enhancing patient compliance in life style
changes, for example formulating realistic goals with
patients, empathetic communication by physicians, being
sensitive to the general stigma of obesity, planning
individualized weight loss and physical activity programs,
encouraging self-efficacy, explaining treatment and its
benefits, motivating patients to self-monitor diet and
physical activity and arranging regular follow-up clinic. This
strategy also includes reinforcement methods and relapse
prevention techniques to ensure long term sustainability of
change.4,34
Majority of patients with NAFLD take more calories, do
less exercise/physical activity which makes them prone to
insulin resistance and overweight or obesity as compared
to subjects who don't have NAFLD.35 The American
gastroenterology Association recommends a weight loss
of 10% of baseline weight as an initial goal if the patient is
overweight.36
Palmer et al showed that weight reduction is associated
with normalization of transaminases as well as liver
enlargement.37 A Japanese study proved that moderate
weight loss (approximately 6%) is associated with
improvement in insulin resistance and fatty liver.38 An
Israeli study on 48 subjects who underwent dietary
restriction leading to moderate weight loss, showed
improvement in liver enzymes in 96% of the subjects.39
Variety of dietary combinations i.e either low
carbohydrate or low fat are equally effective in weight
reduction, and there is no long term difference in weight
loss or its maintenance after treatment. Moreover, no
specific recommendation favours Atkins, Ornish or South
Beach diets.40 Therefore, diet should be modified on
individual preferences.4 The current American
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Gastroenterology Association recommends low calorie,
high fiber and low fat diet (Mediterranean diet) for
reduction of weight. One should avoid diets containing
saturated fat, soft drinks, meat, and the diet should be low
in omega 3 acid, because these diets do lead to NAFLD.36
Physical Activity:
Physical activity (PA) plays a protective role in NAFLD.41 PA
includes structured exercise, involves aerobic activities of
moderate to vigorous intensity (e.g., jogging, brisk
walking, bicycling, swimming, skiing, and ball games) and
resistance training which comply with current exercise
recommendations as well as other leisure time tasks
performed at low intensity below current
recommendations for improving cardio respiratory fitness
(for example casual walking, bicycling, dancing and non-
structural lifestyle activities such as gardening,
housework, hobbies and yoga).42 It has been seen that
weight reduction associated with dietary restriction are
not long lasting and often the weight returns to its
baseline once food restriction is stopped. Weight loss and
improvement in physical activity shows histological
improvement too.43 Diabetes prevention program
research group suggest that exercise adherence appears
to be more sustainable than weight loss over time
therefore every effort should be made to encourage
physical activity (exercise).44 Studies have also shown low
prevalence of metabolic syndrome in subjects who
adhere to increased physical activity and have higher
muscle strength and higher cardio respiratory fitness.
Studies have shown that physical activity leads to a
reduction of risk of type 2 DM, IR, HTN and
dyslipidaemia.45,46 Majority of these clinical effects might
be mediated by changes in the release of adipocytokines
(leptin, adiponectin and resistin), which are implicated in
the development of hepatic steatosis, inflammation and
fibrosis. A study from North America has shown that
moderate intensity aerobic exercise has a beneficial effect
on insulin resistance and alters substrate use in skeletal
muscle.47 Another study revealed that physical activity
enhances insulin sensitivity and glucose homeostasis
through insulin sensitization along with facilitating
glucose uptake, in the absence of weight loss.48 Physical
activity (exercise) also decreases liver triglycerides within
liver by stimulation of lipid oxidation and inhibition of
hepatic lipid synthesis.49
A study from Australia on 141 patients with NAFLD has
shown a significant improvement in liver enzymes in
patients who adhered to PA of 150min/week or more and
those who increased their fitness. This effect was
independent of any weight change. Another study on
obese patients showed moderate improvement in
hepatic fat without losing weight, when aerobic exercise
was done for 4 weeks only.50
Pharmacological treatment:
At present there is no registered drug treatment for
NAFLD. Earlier studies suggest that insulin sensitizers and
antioxidants may confer some benefit whereas
ursodeoxycholic acid (UDCA) and pentoxiphyline have
not proved to be of any benefit in NAFLD in clinical trials.24
Surgical treatment:
Bariatric surgery is only helpful in patients who are
morbidly obese and had shown benefit in NAFLD with
NASH.24
Conclusion
NAFLD is an emerging problem and can cause significant
morbidity and mortality if individuals don't adopt healthy
life style such as regular exercise and a weight
maintenance diet. Since there is no approved treatment
for NAFLD we need to educate Pakistani population about
healthy life style. Also population based studies in our
country are needed so that we can protect our population
from a new epidemic. 
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